Quell launches chill phase 1/2 trial for novel cartreg therapy
Company targets new approach to treating rheumatoid arthritis and systemic sclerosis
Read More
Author: John Pinching
Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
Early data show faster viral clearance and favourable safety in mild to moderate COVID‑19
Read More
FDA approves once‑weekly Sogroya for wider paediatric use
New authorisation extends treatment to children with ISS, SGA and Noonan syndrome
Read More
SolasCure trial shows faster healing with Aurase Wound Gel
Phase 2 study reports significantly accelerated debridement and wound repair in venous leg ulcers
Read More
Gilead data show investigational HIV combination maintains viral suppression
New phase 3 results highlight potential alternative for adults switching from complex regimens
Read More- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
